Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 9Burkitt Lymphoma 7Lung Neoplasms 6Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Carcinoma, Non-Small-Cell Lung 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Sarcoma, Ewing 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Plasmablastic Lymphoma 3Multiple Myeloma 3Lymphoma 3Leukemia 3Hodgkin Disease 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Immunoblastic Lymphadenopathy 2HIV Infections 2Ganglioneuroblastoma 2Congenital Abnormalities 2Blast Crisis 2Anemia, Refractory, with Excess of Blasts 2Wilms Tumor 1

Interventions

pembrolizumab 1atezolizumab 1PT-100 dipeptide 1PM 01183 1Etoposide 1EC regimen 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Etoposide × 30 days × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡